IFNA17 and cutaneous melanoma: The authors concluded that IFN-α therapy demonstrated improvement in both RRFS (risk reduction = 18%) and OS (risk reduction = 11%) of patients with high-risk cutaneous melanoma in a statistically significant fashion.